TrialBreast cancer research and treatment2026

Efficacy, safety, and biomarker analysis of neoadjuvant camrelizumab plus apatinib as a chemotherapy-free strategy for early-stage triple-negative breast cancer: a phase II study.

Zhenluan Tian et al.PubMed ↗Publisher ↗

No numbers read from the abstract.